Program in Novel Biotherapeutics (PINB)


To promote and accelerate early phase clinical development of novel biotherapeutics by building matrix partnerships between interdisciplinary and inter-institutional laboratory and clinical investigators.

Goals include:

  1. To provide a centralized and accessible translational infrastructure available to academic investigators from all Penn Institutions and CHOP that will support and enable bench to bedside research.
  2. To facilitate interaction across areas of diversified experience and range of therapeutic modalities towards cross-disciplinary clinical development.
  3. To train new and junior investigators, in part through educational modules, to promote the field of translational research in novel biotherapeutics.
  4. To support the bioengineering of devices and processes for optimal delivery and targeting of therapeutics. Example devices include both compliant polymer scaffolds for cell growth in vitro or in situ and also polymeric carriers for both drugs and Antisense/siRNA.
  5. To advance the testing of promising cellular and gene therapeutics into later stage clinical development. Examples of cell therapy include tailoring of pre-differentiation strategies for human Mesenchymal Stem Cells and also assays for cell and molecular immunocompatibility with human Macrophages.
  6. To establish the University of Pennsylvania and CHOP as leaders in translational research in the U.S.

PINB Co-Directors

Carl June, MD – Professor
Department of Pathology and Laboratory Medicine
Director of Translational Research of the Abramson Cancer Center

Dennis Discher, PhD – Professor
School of Engineering and Applied Science
Department of Chemical & Biomolecular, Mechanical, and Bio-Engineering

General inquiries can be sent to